INS and Hypoglycemia: The objective of the DELIVER High Risk study was to compare the 12‐month clinical effectiveness of Gla‐300 versus first‐generation BIAs (Gla‐100 or insulin detemir [IDet]) in patients with T2D who were at higher risk of hypoglycaemia and were switching from one BIA to a different BIA (Gla‐100 or IDet to Gla‐300, and from Gla‐100 to IDet or from IDet to Gla‐100).